Key Highlights

  • Revenues were USD 7,557 thousand versus 12,807 thousand, and manufacture and Supply Revenue was USD 6,659 thousand versus 11,467 thousand.
  • The loss from operations was USD 14,469 thousand versus 11,479 thousand, and total costs and expenses were USD 22,026 thousand.
  • The net loss was USD 16,496 thousand versus 15,446 thousand, and the loss per share was USD 0.13 versus 0.14.
  • The FDA has set a March 16, 2027 PDUFA goal date for the Class 2 resubmission of the Anaphylm NDA.

Revenues by Category

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a biopharmaceutical company that is the exclusive manufacturer of four commercialized products marketed by its licensees, filed its Quarterly Report for the period ended September 30, 2026. Revenues for the third quarter were USD 7,557 thousand, compared with USD 12,807 thousand in the third quarter of 2025.

Manufacture and supply revenue was USD 6,659 thousand versus USD 11,467 thousand. License and Royalty revenue was USD 824 thousand versus USD 1,038 thousand, and co-development and research fees were USD 74 thousand versus USD 302 thousand.

For the nine months, revenues were USD 35,822 thousand versus USD 31,530 thousand. Manufacture and supply revenue was USD 27,363 thousand versus USD 28,243 thousand, and license and royalty revenue was USD 7,545 thousand versus USD 2,667 thousand. The company noted that Zevra-related one-time royalty revenues of USD 5,000 thousand were recognized during the nine months.

Analyst estimates were EPS of negative USD 0.12 against reported EPS of negative USD 0.13.

Costs and Operating Loss

Manufacture and supply costs were USD 3,606 thousand versus USD 4,506 thousand. Research and Development expense was USD 4,251 thousand versus USD 4,530 thousand, and selling, general and administrative expense was USD 14,169 thousand versus USD 15,250 thousand. Total costs and expenses were USD 22,026 thousand versus USD 24,286 thousand.

The loss from operations was USD 14,469 thousand versus USD 11,479 thousand. For the nine months, the loss from operations was USD 26,896 thousand versus USD 42,212 thousand.

Net Loss and Liquidity

Interest expense was USD 1,845 thousand versus USD 2,779 thousand, interest expense related to royalty obligations was USD 973 thousand versus USD 1,433 thousand, and interest income and other income, net, was USD 853 thousand versus USD 306 thousand. The net loss was USD 16,496 thousand versus USD 15,446 thousand. Basic and diluted loss per share was USD 0.13 versus USD 0.14, on 125,548,783 weighted average shares versus 110,584,371.

For the nine months, the net loss was USD 47,417 thousand versus USD 51,924 thousand, which included a loss on extinguishment of Debt of USD 11,683 thousand. The loss per share for the nine months was USD 0.38 versus USD 0.51.

Cash and cash equivalents were USD 90,349 thousand at September 30, 2026. The company stated that its existing cash and cash equivalents, expense management activities, potential asset sales or product outlicensing, and access to the Equity capital markets, including the ATM facility, provide Liquidity to fund operating needs for at least the next twelve months. No shares were sold under the ATM Facility in the third quarter, and the remaining authorized balance was USD 73,000 thousand as of September 30, 2026.

Anaphylm and Items to Follow

Aquestive is advancing Anaphylm (dibutepinephrine) sublingual film for Type 1 allergic reactions, including anaphylaxis, and an epinephrine topical gel for dermatological conditions through its AdrenaVerse platform of more than 20 epinephrine prodrugs. The FDA issued a Complete Response Letter dated January 30, 2026, and the company has submitted a Class 2 resubmission of the Anaphylm NDA with a PDUFA goal date of March 16, 2027.

The filing also refers to potential submissions in Canada and the European Union for Anaphylm. Investors can follow the FDA review, the company's commercial launch preparations, and manufacture and supply revenue, which was USD 6,659 thousand in the quarter.